Use of Remdesivir for treatment of COVID-19 patients

Author Details
Author (Corporate)
Publication Date 2020
Content Type


Reports and information relating to the use of the antiviral medication Remdesivir for treatment of patients diagnosed with COVID-19 (coronavirus).

Further information:

This medication is sold under the brand name Veklury. It is developed by bio-pharmaceutical company Gilead Sciences.

As the COVID-19 (coronavirus) pandemic unfolded, this medication was increasingly seen as a valid treatment for patients. Research was conducted to understand the effects on tackling this virus, following effective treatment against previous respiratory syndromes.

On 30 April 2020, the European Medicines Agency (EMA) started a rolling review of data on the use of Remdesivir in COVID‑19. The application for the marketing authorisation was submitted to the EMA on 5 June. EMA’s human medicines committee (CHMP) recommended on 25 June granting a conditional marketing authorisation to Veklury for the treatment of COVID-19 in adults and adolescents from 12 years of age with pneumonia who require supplemental oxygen.

On 3 July, this medication became the first treatment to be given a conditional marketing authorisation. The authorisation was provided just days after the company allocated nearly all of its supply of Remdesivir to the United States over a period of 3 months, raising concerns about availability elsewhere. This medication had already been made available on the United Kingdom's NHS in late May.

The European Commission signed an agreement with Gilead Sciences on 28 July to secure treatment doses of Veklury. The deal aimed to ensure the treatment of approximately 30,000 patients and help to cover the existing needs over the following few months. The Commission's Emergency Support Instrument was used to finance the contract.

Related Link(s)
Commentary and Analysis
Wikipedia: Remdesivir
Forbes, 10/03/2020: Buy Gilead...But Not Because Of Remdesivir
Euronews, 25/06/2020: What is Remdesivir, the first drug put forward to treat COVID-19 in Europe?
The Conversation, 03/07/2020: The US has bought most of the world’s remdesivir. Here’s what it means for the rest of us
Deutsche Welle, 09/07/2020: Is compulsory licensing of remdesivir a feasible option?

The New York Times, 23/03/2020: Coronavirus Patients in Limbo as Gilead Suspends Emergency Drug Access
BBC News, 23/04/2020: Hopes dashed as coronavirus drug remdesivir 'fails first trial'
Politico, 30/04/2020: EU drugs agency evaluates potential coronavirus treatment
BBC News, 26/05/2020: Coronavirus: UK authorises anti-viral drug remdesivir
Euronews, 25/06/2020: Remdesivir becomes first COVID-19 drug put forward for use in the EU
British Medical Journal: News, 29/06/2020: Covid-19: Remdesivir is recommended for authorisation by European Medicines Agency
Politico, 30/04/2020: EU drugs agency evaluates potential coronavirus treatment
The Wall Street Journal, 05/05/2020: Gilead Seeks Deals With Other Drugmakers to Boost Supply of Covid-19 Drug
Politico, 25/06/2020: EU agency backs first COVID-19 treatment
Reuters, 25/06/2020: Gilead's remdesivir set to become Europe's first COVID-19 therapy
The Guardian, 30/06/2020: US secures world stock of key Covid-19 drug remdesivir
TIME, 01/07/2020: European Health Experts Concerned by U.S. Hoarding of Only Licensed Coronavirus Drug
TRT World, 01/07/2020: Germany says remdesivir supplies sufficient to treat Covid-19 patients
Bloomberg, 01/07/2020: European Union in Talks With Gilead to Secure Covid Drug Supply
EUObserver, 02/07/2020: EU silent on US buying up world's remdesivir supplies
The Independent (UK), 02/07/2020: Remdesivir: EU in talks to secure doses of coronavirus drug after US bought up global supply
Deutsche Welle, 03/07/2020: Coronavirus: EU approves COVID-19 drug remdesivir
Reuters, 03/07/2020: Gilead's COVID-19 antiviral remdesivir gets conditional EU clearance, 08/07/2020: Remdesivir Becomes the First Covid-19 Treatment Approved in Europe
France24, 09/07/2020: Covid-19 drug buyout: US's EU representative denies 'America First' policy on Remdesivir
The Irish Times, 29/07/2020: Coronavirus: European Union signs Remdesivir deal with Gilead
Reuters, 29/07/2020: EU buys remdesivir to treat 30,000 COVID patients, seeks more
Bloomberg, 29/07/2020: EU, Gilead Reach Deal on Supply of Antiviral Drug Remdesivir
RTÉ News, 29/07/2020: EU buys enough remdesivir to treat 30,000 Covid cases, seeks more
Politico, 29/07/2020: Commission inks deal for COVID-19 treatment remdesivir
EUObserver, 30/07/2020: EU secures remdesivir supplies for 30,000 patients

EU EMA: Press Release, 03/04/2020: EMA provides recommendations on compassionate use of remdesivir for COVID-19
US NIAID: News Release, 29/04/2020: NIH Clinical Trial Shows Remdesivir Accelerates Recovery from Advanced COVID-19
EU EMA: Press Release, 30/04/2020: EMA starts rolling review of remdesivir for COVID-19
EU EMA: Press Release, 25/06/2020: First COVID-19 treatment recommended for EU authorisation
US FDA: News, 25/06/2020: Partnering with the European Union and Global Regulators on COVID-19
Gilead Sciences: Press Release, 03/07/2020: European Commission Grants Conditional Marketing Authorization for Gilead’s Veklury® (remdesivir) for the Treatment of COVID-19
European Commission: Press Release, 29/07/2020: European Commission secures EU access to Remdesivir for treatment of COVID-19

Subject Categories
Subject Tags